文献速递神经肿瘤

贝伐珠单抗联合伊立替康联合或不联合伽玛刀放射外科治疗高级别胶质瘤同步放化疗失败后的疗效

Bevacizumab plus irinotecan with or without gamma knife radiosurgery after failure of concurrent chemo-radiotherapy for high-grade glioma.
PubMed 文献 · J Neurooncol · 2022-01-30

回顾性分析2015年1月至2020年12月在Samsung Medical Center治疗的203例活检证实的高级胶质瘤患者,评估贝伐珠单抗联合伊立替康联合或不联合伽玛刀放射外科的疗效与安全性。中位总生存期8.73个月,中位无进展生存期4.36个月;68例(33.4%)患者在贝伐珠单抗联合伊立替康前接受伽玛刀放射外科,其总生存期显著延长(10.13个月 vs 8.26个月,p=0.012)。结论认为贝伐珠单抗联合伊立替康耐受良好且中等有效,联合伽玛刀放射外科可带来显著总生存获益且安全性可控,可考虑作为潜在治疗选择。

要点

  • 贝伐珠单抗联合伊立替康治疗高级别胶质瘤同步放化疗失败后中位总生存期8.73个月。
  • 伽玛刀放射外科联合贝伐珠单抗联合伊立替康较单用后者显著延长总生存期(10.13 vs 8.26个月,p=0.012)。
  • 联合伽玛刀放射外科未增加不良事件发生率,安全性可控。

核心结论

  • 贝伐珠单抗联合伊立替康在高级别胶质瘤患者中耐受良好且中等有效。
  • 在贝伐珠单抗联合伊立替康前加用伽玛刀放射外科可带来显著总生存获益且安全性可控,作者认为可考虑作为潜在治疗选择。

研究设计与样本

  • 回顾性收集2015年1月至2020年12月在Samsung Medical Center治疗的活检证实高级别胶质瘤(胶质母细胞瘤或间变性星形细胞瘤)患者的临床数据。
  • 共纳入203例患者,评估贝伐珠单抗联合伊立替康联合或不联合伽玛刀放射外科的总生存期、无进展生存期及安全性。

主要发现

  • 中位总生存期为8.73个月(95%CI:7.27-10.18),中位无进展生存期为4.36个月(95%CI:3.75-4.97)。
  • 68例(33.4%)患者在贝伐珠单抗联合伊立替康前接受伽玛刀放射外科,其总生存期显著延长(10.13个月,95%CI:8.65-11.60 vs 8.26个月,95%CI:7.01-9.51,p=0.012)。
  • 任何级别最常见不良事件为中性粒细胞减少(36.9%)和血小板减少(22.6%)。
  • 接受伽玛刀放射外科的患者与未接受者的不良事件发生率无差异。

临床怎么用

  • 作者认为,对于同步放化疗失败后的高级别胶质瘤患者,贝伐珠单抗联合伊立替康前加用伽玛刀放射外科可考虑作为潜在治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Concurrent chemo-radiotherapy (CCRT) with temozolomide (TMZ) is a standard first-line treatment for high-grade glioma. However, if CCRT with TMZ treatment fails, second-line treatment options have limited value. Bevacizumab plus irinotecan is the only available treatment option for such patients. The role of gamma knife radiosurgery (GKS) in patients with high-grade gliomas is not well-established. In this study, we evaluated the efficacy and safety of bevacizumab plus irinotecan with or without GKS in the treatment of high-grade glioma patients who progressed after initially being treated with CCRT with TMZ. METHODS: We collected clinical data of patients with biopsy-proven high-grade glioma (glioblastoma multiforme (GBM) or anaplastic astrocytoma) who were treated at Samsung Medical Center from January 2015 to December 2020, retrospectively. We evaluated the overall survival (OS), progression-free survival (PFS), and safety of bevacizumab plus irinotecan with or without GKS. RESULTS: In total, 203 patients were diagnosed with high-grade glioma, including GBM and anaplastic astrocytoma. The median OS was 8.73 months (95% confidence interval [CI]: 7.27-10.18), and the median PFS was 4.36 months (95% CI: 3.75-4.97). Sixty-eight (33.4%) patients underwent GKS prior to bevacizumab plus irinotecan treatment, which led to a significantly prolonged OS (10.13 months, 95% CI: 8.65-11.60 vs. 8.26 months, 95% CI: 7.01-9.51, p = 0.012). The most common adverse events of any grade were neutropenia (36.9%) and thrombocytopenia (22.6%). However, the incidence of adverse events in patients who underwent GKS prior to bevacizumab plus irinotecan was not different compared with those in patients who did not undergo GKS. CONCLUSIONS: Bevacizumab plus irinotecan was well-tolerated and moderately effective in patients with high-grade gliomas. The addition of GKS prior to bevacizumab plus irinotecan led to a significant OS benefit with a manageable safety profile. GKS prior to bevacizumab plus irinotecan can therefore be considered a potential treatment option for these patients.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Lee YP, Jung HA, Lee MS, et al. Bevacizumab plus irinotecan with or without gamma knife radiosurgery after failure of concurrent chemo-radiotherapy for high-grade glioma. J Neurooncol. 2022. PMID: 35094201. doi:10.1007/s11060-021-03930-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。